Drugs Are Not Microchips: Whither Industrial Policy In The Life Sciences?

被引：0

作者：

Morrison, J. Stephen ^{[1
]}

Simoneau, Michaela ^{[1
]}

机构：

[1] Ctr Strateg & Int Studies, Washington, DC 20006 USA

来源：

HEALTH AFFAIRS | 2023年 / 42卷 / 08期

关键词：

D O I：

10.1377/hlthaff.2023.00680

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Events such as Russia's invasion of Ukraine in February 2022 have heightened global awareness of the potential for sudden market upheaval and the need for proactive measures to protect supply chains, including in the life sciences. But advancing an industrial policy on drugs requires several unique conditions-including a continued sense of acute threat among the US and its allies, ample public-sector funding, real-time data, industry buy-in, and bipartisan support in Congress-that are currently not present in the US.

引用

页码：1058 / 1061

页数：4

共 31 条

[1]

Advanced Regenerative Manufacturing Institute, 2022, Essential medicines supply chain and manufacturing resilience assessment

[2]

Baker Stephanie, 2020, Bloomberg

[3]

Baptista E, 2023, Reuters

[4]

Brenan Megan, 2022, GallupSeptember 9

[5]

Burr R, 2023, StatJul 11

[6]

Bustillo X, 2023, NPRMay 31

[7]

Cave D, 2023, New York TimesMay 20

[8]

Chen L, 2023, ReutersApr 26

[9]

Cullison T, 2022, The Department of Defense contributions to pandemic response

[10]

Department of Defense, 2023, Press release, DoD releases biomanufacturing strategy

← 1 2 3 4 →